Custom formulations of popular weight loss medications have surged in popularity due to the high costs of FDA-approved drugs.

Strive Compounding Pharmacy sues Eli Lilly and Novo Nordisk over alleged GLP-1 weight loss drug competition limits. Read more here.

As a youth activist in Colorado, I’ve spent years organizing around the issues that shape our generation’s lives — and across ...

In spring 2025, the Food and Drug Administration (FDA) resolved and ended the GLP-1 medications shortage, subsequently releasing declaratory orders that neither outsourcing compounding pharmacies or ...

The Food and Drug Administration (FDA) recently declared an end to the shortage of semaglutide (Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound), categorized broadly as GLP-1 weight loss ...

Compounding pharmacy sues Eli Lilly and Novo Nordisk alleging antitrust violations to restrict compounded GLP-1 medication access and limit competition.

More than 4,400 lawsuits have been filed since millions of Americans embraced GLP-1 drugs like Ozempic, Wegovy and Mounjaro to lose weight.

Strive Specialities Inc., a major provider of compounded medicines, filed a federal lawsuit against pharmaceutical giants Eli ...

Are compounded GLP-1s for weight loss safe? GLP-1s (glucagon-like peptide-1 receptor agonists) are medications used to treat type 2 diabetes and obesity. You’ve probably heard of them under brand ...

By Maggie Fick and Mrinalika Roy Jan 12 (Reuters) - Novo Nordisk CEO Mike Doustdar said on Monday as many as 1.5 million patients in the U.S. may be using compounded versions of blockbuster GLP-1 ...

Drugmakers Eli Lilly and Novo Nordisk have been sued in Texas by a compounding pharmacy that alleges they are illegally blocking access to customized versions of their blockbuster weight-loss ...